Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 26, 1996 - Issue 2
54
Views
20
CrossRef citations to date
0
Altmetric
Research Article

Glucuronidation of diflunisal in liver and kidney microsomes of rat and man

&
Pages 123-131 | Received 07 Aug 1995, Published online: 22 Sep 2008
 

Abstract

1. The glucuronidation of diflunisal to its phenolic (DPG) and acyl glucuronide (DAG) was measured in vitro using microsomes prepared from rat (n = 4) and human (n = 6) liver and kidney tissue. UGT activities towards bilirubin, 4-nitrophenol and (—)-morphine were also determined.

2. β-Glucuronidase activity towards phenolphthalein glucuronide was much lower in microsomes prepared from human liver (45.2±3.1 Fishman Units/mg protein), human kidney (22.0±3.3 FU/mg), and rat kidney (25.1±2.5 FU/mg) as compared with rat liver (118.7±8.8 FU/mg).

3. The formation rate of DAG significantly increased when saccharo-1,4-lactone, a β-Glucuronidase inhibitor, was added to the rat liver microsomal incubation medium. β-Glucuronidase inhibition, however, had little effect on the formation rate of DAG in human liver microsomes, and no effect in rat and human kidney microsomes. The formation of DPG was not affected by the microsomal β-glucuronidase activity.

4. Unlike rat kidney microsomes, which only formed DAG, human kidney microsomes formed both diflunisal glucuronides. Formation of both diflunisal glucuronides in human kidney microsomes (Vmax = 0.97 ± 0.21 and 0.27 ± 0.07 nmol/min/mg for formation of DAG and DPG respectively) represented 60-70 % of the activity found in liver microsomes (Vmax = 1.58 ± 0.32 and 0.40 ± 0.08 nmol/min/mg for formation of DAG and DPG respectively).

5. These results demonstrate that the in vitro glucuronidation rate of diflunisal may be affected by the microsomal β-glucuronidase activity particularly when using rat liver microsomes. Our results also demonstrate that the human kidney has an important UGT-activity towards diflunisal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.